Grant & Eisenhofer serving leading role in coordinated litigation over Gilead’s TDF-based HIV medications
Plaintiff(s):
Patients prescribed Gilead’s tenofovir disoproxil fumarate (TDF) antiretroviral drugs
Case type / claims:
Coordinated mass tort litigation alleging that Gilead negligently designed, manufactured and marketed TDF-based HIV medications (including Viread, Truvada, Atripla, Complera and Stribild) that caused chronic kidney disease and bone density loss, while deliberately delaying the development and release of a safer alternative, tenofovir alafenamide (TAF).
Defendant(s):
Gilead Sciences, Inc.
Jurisdiction:
State of California Superior Court, San Francisco County
Year:
Active
Outcome:
- Bellwether trials began in July 2022.
- In January 2024, the California Court of Appeal allowed plaintiffs’ litigation to proceed.
- In May 2024, the California Supreme Court granted Gilead’s petition to review.
